• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Denmark·Healthcare·NOVO-B.CO
Held by 2 Gurus
Share

Novo Nordisk A/S Stocks

DKK 335.4Last Updated 28.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

DKK 216.63B

DKK 335.4
Key Takeaways

Risk factor

Low default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Latest news

29.07.2026 22:06

Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

21.07.2026 21:08

Novo has filed a lawsuit against its competitor, Eli Lilly, over advertisements for weight-loss drugs

23.06.2026 19:53

Motley Fool analyst sees Viking as 'dark-horse threat' to Eli Lilly and Novo Nordisk

08.06.2026 18:30

'Eli Lilly pulls ahead': investors praise new obesity drug

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Novo Nordisk A/S, along with its affiliated companies, focuses on the discovery, production, and global sale of pharmaceutical goods. Its market presence extends across Europe, the Middle East, Africa, North America, and various Asian territories, including Mainland China, Hong Kong, and Taiwan. The company's activities are divided into two main categories: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division offers therapeutic solutions for conditions such as diabetes, obesity, cardiovascular health, and other developing medical areas. Meanwhile, the Rare Disease division provides treatments for unusual blood conditions, uncommon endocrine disorders, and hormone replacement therapies. Beyond its drug portfolio, Novo Nordisk also manufactures medical devices like insulin pens, growth hormone pens, and injection needles. Furthermore, it develops intelligent tools for diabetes management, including advanced smart insulin pens and the Dose Check application, designed to assist with insulin dosage guidance. The company holds a cooperative agreement with Aspen Pharmaceuticals for the manufacturing of insulin products. Novo Nordisk A/S was founded in 1923 and its corporate headquarters are located in Bagsvaerd, Denmark.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of NOVO-B.CO is 319 and suggests 0.527% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 00:34

A War Between the U.S. and Iran Could Drag On for Several Months — Bloomberg

30.07.2026 00:08

Google has disbanded its Nobel Prize-winning team. Some of its members will join Anthropic

29.07.2026 23:01

The Fed has kept interest rates unchanged for the fifth consecutive time. What's next?

29.07.2026 22:23

"It's a Matter of Lost Trust": Chipmakers Lost More Than $1 Trillion in Market Capitalization in Two Days

29.07.2026 22:06

Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026